Psoriatic Arthritis Pipeline Outlook Report 2024 (Updated)

DelveInsight's, "Psoriatic Arthritis Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in the Psoriatic Arthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Psoriatic Arthritis Pipeline Report
• Over 20+ Psoriatic Arthritis companies are evaluating 25+ Psoriatic Arthritis pipeline therapies in various stages of development, and their anticipated acceptance in the Psoriatic Arthritis market would significantly increase market revenue
• The leading Psoriatic Arthritis Companies working in the market include Pfizer, selection Therapeutics GmbH, Jiangsu HengRui Medicine Co., Ltd., Nimbus Lakshmi Inc., Hansoh Bio Medical R&D Company, Bio-Thera Solutions, MylanInc., ACELYRIN Inc., and others.
• Promising Psoriatic Arthritis Pipeline Therapies in the various stages of development include NDI-034858, Alefacept, Methotrexate, Etanercept, UCB4940 40 mg, si-544, Methotrexate (MTX), and others.
• April 2024: Sun Pharmaceutical Industries Limited announced a study of Phase 3 clinical trials for TILD. This is a randomized, double-blinded, placebo-controlled, Phase 3 study to evaluate the efficacy and safety of tildrakizumab compared to placebo in anti-TNF naïve subjects with active PsA.
• April 2024: Novartis Pharmaceuticals announced a study of Phase 3 clinical trials for AIN457. Optional open label, roll over extension study to investigate the efficacy and safety of secukinumab treatment in Juvenile Idiopathic Arthritis (JIA) subtypes of Juvenile Psoriatic Arthritis (JPsA) and Enthesitis Related Arthritis (ERA).

Request a sample and discover the recent advances in Psoriatic Arthritis Treatment Drugs @ Psoriatic Arthritis Pipeline Outlook Report- https://www.delveinsight.com/sample-request/psoriatic-arthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

In the Psoriatic Arthritis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Psoriatic Arthritis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Psoriatic Arthritis Overview
Psoriatic arthritis is a type of arthritis linked with psoriasis, a chronic skin and nail disease. Psoriasis causes red, scaly rashes and thick, pitted fingernails. Psoriatic arthritis is similar to rheumatoid arthritis (RA) in symptoms and joint swelling (inflammation). Psoriatic arthritis (PsA) is a chronic inflammatory arthritis associated with psoriasis (PsO) and is found in about 20% of such patients with psoriasis.

Find out more about Psoriatic Arthritis Therapeutics Assessment @ Psoriatic Arthritis Preclinical and Discovery Stage Products- https://www.delveinsight.com/sample-request/psoriatic-arthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Psoriatic Arthritis Emerging Drugs Profile

• Sotyktu: Bristol Myers Squibb
Sotyktu (deucravacitinib) is an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor with a unique mechanism of action, representing a new class of small molecules. It is the first selective TYK2 inhibitor in clinical studies across multiple immune-mediated diseases. Bristol Myers Squibb scientists designed Sotyktu to selectively target TYK2, thereby inhibiting signaling of interleukin (IL)-23, IL-12 and Type 1 interferons (IFN), key cytokines involved in the pathogenesis of multiple immune-mediated diseases. Sotyktu achieves a high degree of selectivity by binding to the regulatory domain of TYK2, resulting in allosteric inhibition of TYK2 and its downstream functions. Sotyktu selectively inhibits TYK2 at physiologically relevant concentrations. At therapeutic doses, Sotyktu does not inhibit JAK1, JAK2 or JAK3. Currently, the drug is in the Phase III stage of its development for the treatment of Psoriasis Arthritis.

• HS-10374: Hansoh BioMedical R&D Company
HS-10374 mechanism of action is to inhibit (TYK2) that is tyrosine-kinase 2. TYK2 inhibitors work by blocking the TYK2 protein and the cellular signals that run through it. Those signals can in turn activate other immune proteins and are associated with inflammation. Its route of administration is orally. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Psoriasis Arthritis.

• si-544: selection
si-544, the Company´s lead candidate, selectively blocks Kv1.3, a key ion channel expressed disease-associated effector memory T (TEM) cells. Kv1.3 is essential for the chronic activation and proliferation of these cells which escape the control of the immune system and become malignant. TEM cells drive inflammation in many autoimmune diseases, including atopic dermatitis, psoriasis, rheumatoid arthritis, and multiple sclerosis. Currently, the drug is in the Phase I stage of its development for the treatment of Psoriasis Arthritis.


Psoriatic Arthritis Pipeline Therapeutics Assessment
There are approx. 20+ key Psoriatic Arthritis companies which are developing the Psoriatic Arthritis therapies. The Psoriatic Arthritis companies which have their Psoriatic Arthritis drug candidates in the most advanced stage, i.e. Phase III include, Bristol Myers Squibb.

DelveInsight's Psoriatic Arthritis Report covers around 25+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Psoriatic Arthritis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Intravenous
• Subcutaneous
• Intramuscular
• Topical.

Psoriatic Arthritis Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Learn more about the emerging Psoriatic Arthritis Pipeline Therapies @ Psoriatic Arthritis Clinical Trials Assessment

Scope of the Psoriatic Arthritis Pipeline Report
• Coverage- Global
• Psoriatic Arthritis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Psoriatic Arthritis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Psoriatic Arthritis Companies- Pfizer, selection Therapeutics GmbH, Jiangsu HengRui Medicine Co., Ltd., Nimbus Lakshmi Inc., Hansoh Bio Medical R&D Company, Bio-Thera Solutions, MylanInc., ACELYRIN Inc., and others.

• Promising Psoriatic Arthritis Pipeline Therapies in the various stages of development include NDI-034858, Alefacept, Methotrexate, Etanercept, UCB4940 40 mg, si-544, Methotrexate (MTX), and others.

Dive deep into rich insights for new drugs for Psoriatic Arthritis Treatment, Visit @ Psoriatic Arthritis Market Drivers and Barriers, and Future Perspective- https://www.delveinsight.com/sample-request/psoriatic-arthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Psoriatic Arthritis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Psoriatic Arthritis - DelveInsight's Analytical Perspective
7. Late Stage Products (Phase III)
8. Sotyktu: Bristol Myers Squibb
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. HS-10374: Hansoh BioMedical R&D Company
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. si-544: selection
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Psoriatic Arthritis Key Companies
21. Psoriatic Arthritis Key Products
22. Psoriatic Arthritis - Unmet Needs
23. Psoriatic Arthritis - Market Drivers and Barriers
24. Psoriatic Arthritis - Future Perspectives and Conclusion
25. Psoriatic Arthritis Analyst Views
26. Psoriatic Arthritis Key Companies
27. Appendix

For further information on the Psoriatic Arthritis Pipeline therapeutics, reach out to Psoriatic Arthritis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/psoriatic-arthritis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

List of Important Links-

https://faceblox.mn.co/posts/54148443
https://edpt204w19.mn.co/posts/54148617
https://monewment.mn.co/posts/54148939
https://flexi-vegan.mn.co/posts/54149020
https://network-4526.mn.co/posts/54149059
https://redline-rp.mn.co/posts/54149156
https://sparklabsglobal.mn.co/posts/54149234
https://ajodance.mn.co/posts/54149267
https://datingwithprettygirls.mn.co/posts/54149313
https://dazed.mn.co/posts/54149356
https://moons.mn.co/posts/54149384
https://network-339477.mn.co/posts/54149409
https://match-ideas.mn.co/posts/54149766
https://ceo-codes.mn.co/posts/54149864
https://thinkinvestments.mn.co/members/23360451
https://spoder.mn.co/posts/54150026
https://network-64869.mn.co/posts/54150082
https://network-4448412.mn.co/posts/54150397
https://network-90620.mn.co/posts/54150432
https://network-16648.mn.co/posts/54150462
https://a-d-n.mn.co/posts/54150499
https://fcmcommunity.mn.co/posts/54280862
https://good-stewards.mn.co/posts/54280899
https://listening-works.mn.co/posts/54280919
https://network-20540.mn.co/posts/54280968
https://healing-communities-njde.mn.co/posts/54281001
https://runite.mn.co/posts/54281382
https://jasa-seo.mn.co/posts/54281443
https://louhangaround.mn.co/posts/54281497
https://onwayassociation.mn.co/posts/54281510
https://shaman-leaders.mn.co/posts/54281625
https://virtuous-rubies.mn.co/posts/54281637
https://extinct-networks.mn.co/posts/54281691
https://kingnobleblacksupremacy.mn.co/posts/54282200
https://ledpanellights.mn.co/posts/54282336
https://diy-vision.mn.co/posts/54282407
https://digimac-technologies.mn.co/posts/54282475
https://network-89593.mn.co/posts/54282548
https://tdcommunitynetworks.mn.co/posts/54282663
https://machine-parts-toolbox.mn.co/posts/54282718
https://wecanchat.mn.co/posts/exploring-the-dynamics-of-the-uveitis-market-insights-by-delveinsight
https://jointsnmotion-hub.mn.co/posts/54283557
https://artisthub.mn.co/posts/54283657
https://global-non-profit-network.mn.co/posts/54283837
https://jointsnmotion-hub.mn.co/posts/54283943
https://network-5674633.mn.co/posts/54284190
https://where-this-business-and-businesses.mn.co/posts/54284238
https://travelwithme.social/read-blog/34900

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:
https://www.delveinsight.com/report-store/medical-marijuana-market-insight
https://www.delveinsight.com/report-store/ranibizumab-biosimilars-insight
https://www.delveinsight.com/report-store/vital-sign-monitors-external-remote-patient-monitoring-devices-market

This release was published on openPR.